Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia

Published:2009-03-05 Issue:3 Volume:89 Page:332-341
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Sakamaki Hisashi,Ishizawa Ken-ichi,Taniwaki Masafumi,Fujisawa Shin,Morishima Yasuo,Tobinai Kensei,Okada Masaya,Ando Kiyoshi,Usui Noriko,Miyawaki Shuichi,Utsunomiya Atae,Uoshima Nobuhiko,Nagai Tadashi,Naoe Tomoki,Motoji Toshiko,Jinnai Itsuro,Tanimoto Mitsune,Miyazaki Yasushi,Ohnishi Kazunori,Iida Shinsuke,Okamoto Shinichiro,Seriu Taku,Ohno Ryuzo

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-009-0260-2.pdf

Reference32 articles.

1. Wong S, Witte ON. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol. 2004;22:247–306. doi: 10.1146/annurev.immunol.22.012703.104753 .

2. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038–42. doi: 10.1056/NEJM200104053441402 .

3. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–7. doi: 10.1056/NEJM200104053441401 .

4. Kantarjian HM, O’Brien S, Cortes JE, et al. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 2002;8:2167–76.

5. Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17. doi: 10.1056/NEJMoa062867 .

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia;International Journal of Hematology;2019-11-13

2. The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group;Internal Medicine;2018

3. The role of ethnicity in personalized dosing of small molecule tyrosine kinase inhibitors used in oncology;Translational Cancer Research;2017-12

4. Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study;International Journal of Hematology;2017-04-25

5. Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment;International Journal of Hematology;2017-04-13